ArticleClinical case reports2024

Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.

Jiao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.